Sava Raises $36M Series B for Glucose Monitoring Technology

Executive Summary

• The Capital Injection: London-based bio-wearable developer Sava Technologies raises $36 million in a Series B round led by Ascensia Diabetes Care, bringing total funding to $68 million to advance clinical trials and scale automated micro-fabrication.

• The Structural Shift: Sava's sub-dermal microsensors are approximately ten times shorter than conventional CGM sensor filaments. The design aims to reduce the extent of sensor insertion while maintaining continuous glucose measurement.

• The Commercial Advantage: Ascensia's investment is accompanied by an exclusive European commercialization and distribution agreement, potentially helping Sava bridge the gap between clinical development and market entry.

• The Longevity Investment Thesis: Sava offers potential exposure to longevity infrastructure through continuous biological monitoring. Its immediate commercial opportunity is glucose management; its longer-term upside depends on extending the technology into additional validated biomarkers and clinically actionable applications.

• The Critical Milestones: Pivotal clinical performance, regulatory clearance, manufacturing economics and commercial adoption will determine whether Sava can translate its technical differentiation into a scalable business.

1. The Signal

Capital is moving into technologies designed to make biological measurement more continuous, accessible and actionable. Sava Technologies' $36 million Series B illustrates this shift within medical diagnostics, where advances in biosensing could expand the role of real-time biological data in clinical decision-making.

The London-based company, founded by Imperial College London bioengineers Renato Circi and Rafaël Michali, is developing a continuous glucose monitor (CGM) based on microsensors designed to measure glucose in interstitial fluid beneath the skin.

The round is led by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation, with participation from Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures, Italian Founders Fund, True. and Athletico Ventures. The financing brings Sava's cumulative funding to $68 million.

Alongside the investment, Sava has signed an exclusive European commercialization and distribution agreement with Ascensia. The proceeds will support automated manufacturing scale-up and pivotal clinical studies as Sava advances toward regulatory approval.

The timing matters. Sava is moving from early clinical evidence toward the more capital-intensive stages of medical-device development: demonstrating performance in pivotal trials, establishing reliable production and preparing for commercial deployment.

Ascensia's involvement adds a strategic dimension. Beyond providing capital, it offers a potential route to market through an established diabetes-care business. This could reduce the burden of building a commercial distribution network independently, although commercialization remains contingent on regulatory approval and market adoption.

For longevity investors, the signal extends beyond a new glucose-monitoring device. It is the convergence of biosensing innovation, strategic capital and commercial infrastructure around the continuous measurement of human biology.

The investment question is whether this combination can turn a differentiated sensing technology into a commercially viable medical product — and potentially establish a foundation for broader biological monitoring applications.

2. The Alpha

Sava's investment thesis rests on three potential sources of value: differentiated sensor architecture, strategic commercialization and the opportunity to extend the technology beyond glucose.

A. Sensor Architecture: Challenging the Established CGM Model

Conventional continuous glucose monitors typically use sensor filaments inserted beneath the skin to measure glucose in interstitial fluid. Abbott's FreeStyle Libre and Dexcom's CGM systems are established examples of this approach.

Sava's platform uses microsensors approximately ten times shorter than conventional CGM filaments. The design aims to access interstitial fluid closer to the skin's surface while reducing the extent of sensor insertion.

This creates a potential product differentiation opportunity across three dimensions.

• User experience: A shorter sensor may reduce the physical burden associated with insertion and improve acceptability, provided clinical performance and wear reliability are maintained.

• Sensor performance: The architecture offers a different approach to the interaction between the sensor and surrounding tissue. Any advantage in accuracy, stability or tissue response must be established through clinical evidence.

• Manufacturing scalability: Sava is investing in automated micro-fabrication to support higher production volumes. The commercial value will depend on manufacturing yield, consistency and cost.

The strategic question is whether this architecture can deliver a meaningful advantage over established CGMs — not simply whether the sensor is smaller.

Sava reported results from a 46-participant clinical study in February 2026, describing glucose-measurement performance comparable to a leading CGM. This represents an encouraging development milestone, but it does not replace the pivotal evidence and regulatory clearance required for the device's intended clinical use.

The competitive opportunity therefore rests on whether Sava can translate its sensor design into measurable improvements in usability, reliability, manufacturing economics or other attributes that matter to patients and healthcare providers.

B. Capital Meets Distribution: The Ascensia Advantage

Medical-device companies face a difficult transition between technical validation and commercial scale. Clinical development requires substantial capital, while market entry demands manufacturing capacity, regulatory expertise and access to healthcare channels.

Ascensia's participation addresses part of this challenge.

• Commercial infrastructure: Ascensia has an established presence in diabetes care, with products sold in more than 90 countries. Its existing commercial capabilities could provide Sava with a route to market without requiring the company to build an equivalent network from the ground up.

• Strategic alignment: Ascensia's dual role as investor and prospective commercialization partner creates alignment between Sava's development milestones and its commercial ambitions.

• Potential capital efficiency: Leveraging an existing distribution network could reduce certain market-entry costs and shorten the path from approval to commercialization.

However, the agreement does not eliminate the need to demonstrate product demand, competitive pricing or attractive unit economics. Its precise commercial terms and expected financial contribution have not been established by the funding announcement alone.

For investors, the distinction is important: strategic distribution can reduce some go-to-market uncertainty, but it cannot substitute for clinical validation or commercial execution.

The investment thesis is therefore not that Sava has eliminated medtech's commercialization risk. It is that the company has secured a strategic partner that could help address one of the structural challenges facing emerging medical-device businesses.

C. Beyond Glucose: The Potential of a Multi-Biomarker Platform

Sava's longer-term opportunity lies in whether its sensing architecture can be extended beyond glucose monitoring.

The company has identified the potential to develop sensors for additional molecules, including lactate, ketones, cortisol and other biomarkers. These represent potential future applications rather than established commercial capabilities.

The strategic attraction is the possibility of extending a common sensing technology across multiple biological measurements. If technically feasible and clinically validated, this could allow Sava to pursue applications beyond its initial glucose-monitoring product.

The potential areas of application differ:

• Metabolic health: Glucose and potentially ketone monitoring could support specific clinical and health-management applications.

• Physiological monitoring: Selected biomarkers, such as lactate or cortisol, may be relevant to particular clinical, research or performance-related use cases, depending on the measurement technology and intended application.

• Preventive and personalized health: Longitudinal biomarker data could support more individualized assessment when measurements are clinically meaningful and linked to actionable decisions.

Each application would require its own assessment of technical feasibility, measurement accuracy, clinical utility, regulatory requirements and market demand. The ability to measure an additional molecule does not automatically establish a viable product or a new revenue stream.

The investment opportunity lies in whether Sava can turn its differentiated sensing architecture into a commercially viable CGM product — and, over time, extend that platform into additional validated biomarkers. The first would establish the business; the second could expand its strategic value.

3. The Risk/Reward

Capital Vector	Strategic Risk Factor	Volatility Mitigation / Value-Creation Lever
Clinical validation	Early clinical performance may not translate into the accuracy, safety and reliability required for the intended use.	Pivotal clinical studies will provide the evidence needed to support regulatory submissions and assess performance at scale.
Manufacturing scale	Automated manufacturing may encounter yield, consistency or cost challenges as production volumes increase.	Investment in manufacturing automation could improve repeatability and production capacity, subject to demonstrated results.
Regulatory clearance	Delays or failure to obtain the required approvals could postpone commercialization or constrain the permitted use of the device.	Clinical evidence and a defined regulatory-development program provide a pathway toward approval, but do not guarantee it.
Commercial adoption	Established CGM providers have recognized products, clinical relationships and distribution networks. Sava must demonstrate sufficient differentiation to win adoption.	Ascensia's European commercialization agreement offers a potential route to market and may reduce the need to build distribution independently.
Multi-biomarker expansion	Additional analytes may present distinct technical, validation and regulatory challenges.	A reusable sensing architecture could support expansion if individual biomarkers and their intended applications are validated successfully.
Capital efficiency	Sava may require further financing before reaching commercial scale, potentially creating additional dilution.	Milestone-based deployment of Series B capital could help manage execution risk. Future financing needs will depend on clinical, regulatory and commercial progress.

The Investment Variables That Matter Most

Pivotal-trial performance. The next major clinical milestone is demonstrating that Sava's glucose-monitoring technology meets the applicable requirements for its intended use, including non-adjunctive insulin-dosing applications if pursued. Early clinical results should not be treated as equivalent to pivotal-trial success or regulatory clearance.

Manufacturing economics. Sensor miniaturization creates a differentiated design, but the investment case ultimately depends on producing reliable devices at commercially viable costs. Manufacturing yield, quality control, production capacity and unit economics will be key indicators.

Commercial conversion. Ascensia provides a potential distribution advantage, but the agreement's value will be demonstrated through product availability, adoption and revenue rather than the existence of the partnership alone. Pricing, channel economics and the pace of customer uptake remain important unknowns.

Platform validation. Additional biomarkers could broaden the opportunity beyond glucose monitoring. Investors should distinguish the potential value of future applications from the current evidence supporting the initial product. Each new application must demonstrate reliable measurement and a viable clinical or commercial proposition.

Financial transparency. The $36 million raise and $68 million in cumulative funding establish the capital committed to date, but the announced figures do not reveal Sava's valuation, dilution, cash runway, projected revenue, unit economics or distribution terms. Those variables would be needed for a fuller assessment of potential investment returns.

The central risk/reward question is whether Sava can translate a differentiated sensor design into a regulated, manufacturable and commercially adopted product before expanding its ambitions into a broader sensing platform.

4. The Horizon

Over a five-year horizon, Sava's trajectory could progress from a specialized glucose-monitoring product toward a broader molecular sensing platform. Each stage depends on achieving the clinical, regulatory and commercial milestones that precede it.

Years 1–2 | Clinical Validation and Commercial Readiness

The near-term priorities are pivotal clinical studies, regulatory submissions and automated manufacturing scale-up. Sava's announced target is to pursue European approval for non-adjunctive use within approximately 18 to 24 months of its October 2026 announcement.

The decisive indicators will be clinical performance, regulatory progress, production readiness and the company's ability to prepare for commercialization with Ascensia.

The investment thesis at this stage is predominantly clinical medtech: establishing that the initial glucose-monitoring product can meet its intended requirements and progress toward market entry.

Years 3–4 | Commercial Adoption and Platform Development

If the initial product receives the necessary approvals, the focus shifts toward European market penetration, manufacturing economics and sustained demand.

Expansion into other geographic markets, including the United States, would require the relevant regulatory pathway and additional clinical and commercial preparation. Development of additional biomarkers could proceed in parallel, but timelines and launch commitments should not be assumed without company-specific evidence.

For investors, the key transition is from technical validation to commercial proof. Product adoption, manufacturing efficiency and revenue generation would help establish whether Sava can build a sustainable business around its initial technology.

Year 5 | The Potential for a Broader Biosensing Platform

If Sava establishes a successful glucose-monitoring business and validates additional sensing applications, it could evolve beyond a single-product model.

The strategic opportunity is to extend a differentiated glucose-monitoring technology into a broader portfolio of validated biosensing applications. Whether that opportunity translates into durable value will depend on Sava's ability to establish clinical credibility, achieve commercial scale and demonstrate that its platform can succeed beyond its initial application.

Extending Horizons. Elevating Life.